Meta menu:

From here, you can access the Emergencies page, Contact Us page, Accessibility Settings, Language Selection, and Search page.

Open Menu
Nahaufnahme mehrerer Probenröhrchen, die auf einem Tisch liegen. Im Hintergrund ist unscharf der Schriftzug "Charité" auf einem Formular erkennbar.


Here you can find an overview of the funding of the AG Fuchs

You are here:

Currently funded projects

EU, ENDOSCAPE (coordinator):
A clinically applicable non-viral gene delivery technology (Horizon 2020, no. 825730)

Anti-inflammatory glycosides from plants: Identification of cellular targets and examination of structure–function relationships (FU 408/11-1)

Aglaia Oncology Fund II:
Saponin-mediated endosomal escape enhancer technology for controlled intracellular drug delivery

Triterpenoids for controlled cytosolic drug release of targeted tumor therapeutics


Formerly funded projects (selection):

Controlled efficacy increase of tumor-specific toxins by pH-dependent release of saponins from targeted nanoparticles

Development of tumor-activated targeted toxins and their investigation in combination with glycosylated triterpenoids

Saponin-mediated intracellular liberation of chimeric toxins. A new basic technology for cell-targeted tumor therapy

Regulated intramembrane proteolysis of transferrin receptor 1 and the role of the released intracellular domain in signaling of iron metabolism

Development of a novel strategy for cancer therapy by combining chimeric adapter toxins and triterpenoids investigated on mammary gland tumors

Identification and characterization of the Arg-100-transferrin receptor shedding protease

Saporin/saponin transport systems for targeted release of drugs for tumor therapy

Deutsche José Carreras Leukämie-Stiftung:
Controlled intracellular release for increasing the efficacy of an antibody-based combination therapy of CD19/CD22 positive lymphoma and leukemia

Deutsche Krebshilfe:
Rekombinant  fusions proteins for antibody-directed enzyme prodrug therapy (ADEPT) and radio-ADEPT of colon carcinoma  

Generation of a modified apoptin with unique coupling sites for the development of a targeted toxin to induce tumor cell specific apoptosis